TY - JOUR T1 - Higher Comorbidities and Early Death is Characteristic of Hospitalized African-American Patients with COVID-19 JF - medRxiv DO - 10.1101/2020.07.15.20154906 SP - 2020.07.15.20154906 AU - Raavi Gupta AU - Raag Agrawal AU - Zaheer Bukhari AU - Absia Jabbar AU - Donghai Wang AU - John Diks AU - Mohamed Alshal AU - Dokpe Yvonne Emechebe AU - F. Charles Brunicardi AU - Jason M. Lazar AU - Robert Chamberlain AU - Aaliya Burza AU - M.A. Haseeb Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/16/2020.07.15.20154906.abstract N2 - Background African-Americans/Blacks have suffered higher morbidity and mortality from COVID-19 than all other racial groups. This study aims to identify the causes of this health disparity, determine prognostic indicators, and assess efficacy of treatment interventions.Method We performed a retrospective cohort study of clinical features and laboratory data of COVID-19 patients admitted over a five-week period at the height of the pandemic in the United States. This study was performed at an urban academic medical center in New York City, declared a COVID-only facility, serving a majority Black populationResult Of the 1,070 consecutive patients who tested positive for COVID-19, 496 critically ill patients were hospitalized and included in the study. 88% of patients were Black; and a majority (53%) were 61-80 years old with a mean body mass index in the “obese” range. 97% had one or more comorbidities. Hypertension was the most common (84%) pre-existing condition followed by diabetes mellitus (57%) and chronic kidney disease (24%). Patients with chronic kidney disease and end-stage renal disease who received hemodialysis were found to have significantly lower mortality, then those who did not receive it, suggesting benefit from hemodialysis (11%, OR, 0.35, CI, 0.17 - 0.69 P=0.001). Age >60 years and coronary artery disease were independent predictors of mortality in multivariate analysis. Cox Proportional Hazards modeling for time to death demonstrated a significantly high ratio for COPD/Asthma, and favorable effects on outcomes for pre-admission ACE inhibitors and ARBs. CRP (180, 283 mg/L), LDH (551, 638 U/L), glucose (182, 163 mg/dL), procalcitonin (1.03, 1.68 ng/mL), and neutrophil / lymphocyte ratio (8.5, 10.0) were predictive of mortality on admission and at 48-96 hrs. Of the 496 inpatients, 48% died, one third of patients died within the first three days of admission. 54/488 patients received invasive mechanical ventilation, of which 87% died and of the remaining patients, 32% died.CONCLUSIONS COVID-19 patients in our predominantly Black neighborhood had higher mortality, likely due to higher prevalence of comorbidities. Early dialysis and pre-admission intake of ACE inhibitors/ARBs improved patient outcomes. Early escalation of care based on comorbidities and key laboratory indicators is critical for improving outcomes in African-American patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot applicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:SUNY Downstate Institutional Review Board [1587476-1].All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.ACEangiotensin converting enzymeAKIAcute Kidney InjuryaPTTactivated partial thromboplastin timeAlk Phosphatasealkaline phosphataseALTalanine aminotransferaseARBangiotensin II receptor blockersARDSacute respiratory distress SyndromeASTaspartate aminotransferaseBUNblood urea nitrogenBMIbody mass indexCACCOVID-19 associated coagulopathyCADcoronary artery diseaseCIconfidence intervalCKDchronic kidney diseaseCOPDchronic obstructive pulmonary diseaseCRPC-reactive proteinDMdiabetes mellitusDNIdo not intubateDNRdo not resuscitateESRDend stage renal diseaseHIVhuman immunodeficiency virusHThypertensionINRinternational normalized ratioIQRinterquartile rangeLDHlactate dehydrogenaseNLRneutrophil:lymphocyte ratioORodds ratioPTprothrombin timertPCRreal time polymerase chain reactionSUNYState University of New YorkUKUnited Kingdom ER -